Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713287 | 1.00 | PTGS2 (0.68) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL8406886 | 0.88 | CA12 (0.58) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL8325199 | 0.88 | CA12 (0.58) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL28763163 | 0.88 | PTGS2 (0.68) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL8406884 | 0.88 | CA12 (0.58) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL8325197 | 0.87 | PTGS2 (0.53) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL9369592 | 0.86 | KMT2A (0.52) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL9369607 | 0.86 | KMT2A (0.52) | PTGS2CA12CA1CA2TYR | |
| SCHEMBL2775096 | 0.84 | MAOB (0.64) | CA12CA1CA2TYRCA7 | |
| SCHEMBL14634610 | 0.84 | CA12 (0.62) | CA12CA1CA2TYRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1951260-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | Bezwada Biomedical LLC (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053794-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053794-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | COMT, AOX1, UGT1A6 | PTGS2 762/4885CA12 4540/4885CA1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.